Jild 1 № 1 (2025): Iyul - sentyabr
1-8
2025-11-01
Ochiq kirish

Janubiy Orolbo‘yi hududida metabolik jihatdan sog‘lom semizlikka ega odamlarda buyrak faoliyatiga atrof-muhit va metabolik omillarning ta’siri: klinik va funksional tadqiqot natijalari

orcidA.G. Gadaev
orcidDon Eliseo III Lucero-Prisno
orcidR.Q. Dadabaeva
orcidR.I. Turaqulov
orcidI.I. Islomov

Qabul qilingan: 2025-11-24 11:41:28

Nashr etilgan: 2025-11-01

PDF (inglizcha)

Annotatsiya

Maqsad. Janubiy Orolbo‘yi Markaziy Osiyodagi eng ekologik xavfli hududlardan biri bo‘lib, keskin kontinental iqlim, atmosferadagi yuqori darajadagi ifloslanish (PM2.5), suv tanqisligi va uglevod hamda un mahsulotlarini ortiqcha iste’mol qilish bilan tavsiflanadi. Shu sharoitda semizlikning, jumladan metabolik jihatdan sog‘lom semizlik (MHS) fenotipining keng tarqalganligi kuzatiladi — bunda metabolik sindrom belgilari bo‘lmasa ham, ortiqcha vazn saqlanib qoladi. Tashqi ko‘rinishda “metabolik normaga” o‘xshash bo‘lsa-da, bunday bemorlar ekologik omillar uzoq muddat ta’sir qilganda yashirin buyrak disfunktsiyasiga moyil bo‘ladi. Tadqiqotning maqsadi Janubiy Orolbo‘yi hududidagi MHS bo‘lgan bemorlarda ekologik (PM2.5, suvning sho‘rligi, tuproq sho‘rligi) va metabolik omillarning buyrak faoliyatiga ta’sirini baholash, bunda taxminiy glomerulyar filtratsiya tezligi (eGFR) va funksional buyrak rezervi (FBR) ko‘rsatkichlari 6 oylik aralashuvdan oldin va keyin solishtirildi.


Materiallar va usullar. Tadqiqotga 133 nafar ishtirokchi (25–50 yosh) jalb qilinib, ular uch guruhga bo‘lindi: 1-guruh — MHS I daraja (BMI 30–34,9 kg/m²), 2-guruh — MHS II daraja (BMI 35–39,9 kg/m²) va klinik jihatdan sog‘lom shaxslardan iborat nazorat guruhi. Asosiy guruhga azilsartan 10 mg/kun va tuzilgan jismoniy faollik (kuniga ≥60 daqiqa piyoda yurish, haftada ≥5 marta) belgilandi. Buyrak faoliyati CKD-EPI 2021 bo‘yicha hamda FBR testi (0,5% NaCl eritmasi, tana vaznining 0,5%) yordamida baholandi. Kuzatuv muddati 6 oy.


Natijalar. Janubiy Orolbo‘yi bemorlarida eGFR va FBR ko‘rsatkichlari nazorat guruhiga nisbatan sezilarli past edi (eGFR — 126,1 ± 1,7 va 123,7 ± 2,0 ml/min/1,73 m² ga qarshi 131,1 ± 2,2 ml/min/1,73 m²; FBR — 28,3 ± 3,5 % va 24,3 ± 3,6 % ga qarshi 34,1 ± 2,2 %, p < 0,05). 6 oylik aralashuvdan so‘ng MHS I darajadagi bemorlarda FBR 12 % ga oshdi (p < 0,01), MHS II darajadagilarda esa o‘zgarishlar uncha sezilarli bo‘lmadi.


Xulosa. Ekologik stress sharoitida yashovchi MHS bemorlarida metabolik profil saqlangan bo‘lsa-da, erta, subklinik buyrak disfunktsiyasi rivojlanish xavfi yuqori bo‘ladi. Funksional buyrak rezervini baholash buyrakdagi buzilishlarni klinik belgilardan oldin aniqlashga imkon beradi va surunkali buyrak kasalliklarining erta skriningi uchun samarali vosita bo‘lishi mumkin. Tadqiqot natijalari MHS populyatsiyasida azilsartan va tuzilgan jismoniy faoliyatni nefroprotektiv strategiya sifatida qo‘llash maqsadga muvofiqligini tasdiqlaydi.

Kalit so‘zlar

Adabiyotlar ro'yxati

  1. Feng S, Li M, Fei J, et al. Ten-year outcomes after percutaneous coronary intervention versus coronary artery bypass grafting for multivessel or left main coronary artery disease: A systematic review and meta-analysis. J Cardiothorac Surg. 2023;18:54. https://doi.org/10.1186/s13019-023-02101-y.

  2. Raja SG, Ilsley C, De Robertis F, Lane R, et al. Mid-to-long term mortality following surgical versus percutaneous coronary revascularization stratified according to stent subtype: An analysis of 6,682 patients with multivessel disease. PLoS One. 2018;13(2):e0191554. https://doi.org/10.1371/journal.pone.019155 4.

  3. Bajraktari G, Bytyçi I, Henein MY, Alfonso F, Ahmed A, Jashari H, Bhatt DL. Complete revascularization for patients with multivessel coronary artery disease and ST-segment elevation myocardial infarction after the COMPLETE trial: A meta-analysis of randomized controlled trials. Int J Cardiol Heart Vasc. 2020;29:100549. https://doi.org/10.1016/j.ijcha.2020.100549.

  4. Bruno F, Marengo G, De Filippo O, Wanha W, Leonardi S, et al. Impact of complete revascularization on development of heart failure in patients with acute coronary syndrome and multivessel disease: A subanalysis of the CORALYS Registry. J Am Heart Assoc. 2023;12(15):e028475. https://doi.org/10.116 1/JAHA.122.028475.

  5. Carson P, Wertheimer J, Miller A, O’Connor CM, Pina IL, Selzman C, et al. The STICH trial (surgical treatment for ischemic heart failure): Mode-of-death results. JACC Heart Fail. 2013;1:400–407. https://doi.org/10.1016/j.jchf.2013.04.006.

  6. Holmes DR Jr, Davis KB, Mock MB, Fisher LD, Gersh BJ, Killip T 3rd, et al. The effect of medical and surgical treatment on subsequent sudden cardiac death in patients with coronary artery disease: A report from the Coronary Artery Surgery Study. Circulation. 1986;73:1254–1263. https://doi.org/10.1161/01.CIR.73.6.1254.

  7. Huang D, Huo Y, Zhang S, Huang C, Han Y. Prevention of sudden cardiac death after revascularization for coronary heart disease. Int J Heart Rhythm. 2018;3:1–15. https://doi.org/10.3760/cma.j.issn.2095-4 279.2018.01.001.

  8. Kurbanov RD, Mullabaeva GU, Irisov JB. The influence of myocardial revascularization on ventricular arrhythmia in patients with ischemic heart disease. Med Sci. 2017;21(1):103–106.

  9. Zeppenfeld K, Tfelt-Hansen J, de Riva M, Winkel BG, Behr ER, Blom NA, et al. 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur Heart J. 2022;43(40):3997–4126. https://doi.org/10.1093/eurheartj/ehac262.

  10. Bhat A, Gan GC, Tan TC, Hsu C, Denniss AR. Myocardial viability: From proof of concept to clinical practice. Cardiol Res Pract. 2016;2016:1020818. https://doi.org/10.1155/2016/1020818.

  11. Cleland JG, Calvert M, Freemantle N, Arrow Y, Ball SG, Bonser RS, et al. The Heart Failure Revascularisation Trial (HEART). Eur J Heart Fail. 2011;13(2):227–233. https://doi.org/10.1093/eurjhf/ hfq230.

  12. Effect of PCI on health status in ischemic left ventricular dysfunction: Insights from REVIVED-BCIS2. JACC Heart Fail. 2024;12(4):345–354. https://doi.org/10.1016/j.jchf.2024.03.010.

  13. Ndrepepa G, Cassese S, Byrne RA, Bevapi B, et al. Left ventricular ejection fraction change following percutaneous coronary intervention: Correlates and association with prognosis. J Am Heart Assoc. 2024;13(21):e035791. https://doi.org/10.1161/JAHA.124.035791.

  14. Wollmuth J, Patel MP, Dahle T, Bharadwaj A, et al. RESTORE-EF Investigators. Ejection fraction improvement following contemporary high-risk percutaneous coronary intervention: RESTORE-EF study results. J Soc Cardiovasc Angiogr Interv. 2022;1(5):100350. https://doi.org/10.1016/j.jscai.2022.100350.

  15. Bista R, Zghouzi M, Jasti M, Lichaa H, Kerrigan J, et al. Outcomes of percutaneous revascularization in severe ischemic left ventricular dysfunction. Curr Cardiol Rep. 2024;26(5):435–442. https://doi.org/10.1 007/s11886-024-02045-2.

  16. Neumann FJ, Sousa-Uva M, Ahlsson A, Alfonso F, et al. 2018 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on myocardial revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2019;40(2):87–165. https://doi.org/10.1093/eurheartj/ehy394.

  17. Mehta SR, Wood DA, Storey RF, Mehran R, Bainey KR, Nguyen H, et al. COMPLETE Trial Steering Committee and Investigators. Complete revascularization with multivessel PCI for myocardial infarction. N Engl J Med. 2019;381(15):1411–1421. https://doi.org/10.1056/NEJMoa1907775.

  18. Boeken U, Feindt P, Litmathe J, Gams E. Comparison of complete and incomplete revascularization in CABG patients with severely impaired left ventricular function. Z Kardiol. 2004;93(3):216–221. https://doi.org/10.1007/s00392-004-0043-y.

  19. Saraste A, Maaniitty T. Significance of myocardial flow reserve after revascularization. Eur Heart J Cardiovasc Imaging. 2023;24(11):1478–1479. https://doi.org/10.1093/ehjci/jead151.

  20. Ruppar TM, Cooper PS, Mehr DR, Delgado JM, Dunbar-Jacob JM. Medication adherence interventions improve heart failure mortality and readmission rates: Systematic review and meta-analysis of controlled trials. J Am Heart Assoc. 2016;5(6):e002606. https://doi.org/10.1161/JAHA.115.002606.

  21. Üveges Á, Jenei C, Kiss T, et al. Three-dimensional evaluation of the spatial morphology of stented coronary artery segments in relation to restenosis. Int J Cardiovasc Imaging. 2019;35(10):1755–1763. https://doi.org/10.1007/s10554-019-01628-3.

Mualliflar haqida

orcid
A.G. Gadaev
abgadaev@yahoo.com
Tashkent state medical university
orcid
Don Eliseo III Lucero-Prisno
don-eliseo.lucero-prisno@lshtm.ac.uk
London Gigiyena va Tropik Tibbiyot Maktabi
orcid
R.Q. Dadabaeva
rdadabaeva@mail.ru
Toshkent davlat tibbiyot universiteti
orcid
R.I. Turaqulov
rustamturakulov571@gmail.com
Toshkent davlat tibbiyot universiteti
orcid
I.I. Islomov
md.inomjon.islomov@gmail.com
Urganch davlat tibbiyot instituti

Litsenziya

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Qanday iqtibos keltirish kerak

Janubiy Orolbo‘yi hududida metabolik jihatdan sog‘lom semizlikka ega odamlarda buyrak faoliyatiga atrof-muhit va metabolik omillarning ta’siri: klinik va funksional tadqiqot natijalari (A. Gadaev, D. E. III Lucero-Prisno, R. Dadabaeva, R. Turaqulov, & I. Islomov, Trans.). (2025). O‘zbek Ichki Kasalliklar Ilmiy Jurnali, 1(1), 1-8. https://uzsjid.uz/index.php/jour/article/view/12

ISSN 0000-0000 (Online)